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MMS of recurrent and high-risk NMSCs
are most likely to impact the Mohs units
that provide services to those most in
need of this valuable but overused
procedure.
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‘‘Patch’’ing Up Our Tumor Signaling
Knowledge
Scott X. Atwood1,2, Ramon J. Whitson1,2 and Anthony E. Oro1
The tumor suppressor Patched1 (Ptch1) possesses well-described roles in
regulating sonic hedgehog (SHH) signaling in the skin and preventing the
formation of basal cell carcinomas (BCCs). In this issue, Kang et al. extend their
previous work to show that a naturally occurring allele of Ptch1 found in FVB mice
promotes early squamous cell carcinoma (SCC) growth without aberrant activa-
tion of the SHH pathway. The study reveals new roles for Ptch1 that lie at the
nexus between BCC and SCC formation.
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The sonic hedgehog (SHH) signaling
pathway has key roles during embryonic
development, cell fate decisions, and
tumor formation (Hui and Angers,
2011; Ingham et al., 2011). SHH binds
to its receptor Patched1 (Ptch1),
releasing Smoothened (Smo) inhibition
that results in Gli-dependent transcrip-
tion of SHH target genes. Inactivating
mutations in Ptch1 in the skin promotes
formation of basal cell carcinomas (BCCs)
at high frequency and are the cause of
Gorlin syndrome in the germline (Hahn
et al., 1996). Although Gorlin patients
have well-characterized susceptibility
to other SHH-dependent tumors, Ptch1
loss in these patients does not appear to
contribute to excessive SCC develop-
ment. Moreover, sporadic BCCs also rely
on high levels of SHH target gene indu-
ction for tumor growth, providing the
rational for development of a targeted
therapy. Indeed, inhibition of the SHH
pathway with Smo antagonists recently
received Food and Drug Administration
approval for the treatment of late
advanced or metastatic BCCs, and they
have shown impressive efficacy in
Gorlin patients (Atwood et al., 2012).
Although the role for Ptch1 in BCC
tumor suppression is clear, surprisingly
little is known about how this enigmatic
protein functions at a mechanistic level.
Ptch1 is a member of the sterol-sensing
domain family and shares identity
with the ABC transporter family (Ingham
et al., 2011). Although this suggests it
pumps key signaling molecules, none so
far has been identified unequivocably.
Moreover, Ptch1 function in suppressing
Smo, arguably its most oft-written role,
has not been delineated. Although it is
clear that SHH binding to Ptch1 acti-
vates Smo, how the two proteins interact
remains unknown. Initial studies sug-
gested that the two proteins form a
complex and argued for direct allosteric
inhibition (Carpenter et al., 1998;
Murone et al., 1999). However, later
quantitative studies indicated that Ptch1
acts catalytically, suggesting it controls an
enzymatic modifier of Smo function
(Ingham et al., 2000; Taipale et al.,
2002). Recently, entry into the primary
cilium, a microtubule based organelle,
has been shown to be important for Smo
function, and Ptch1 appears to regulate
ciliary entry in an as yet unknown
manner (Rohatgi et al., 2007).
Ptch1FVB promotes Ras-induced skin
tumorigenesis
Distinct from its role in controlling the
SHH pathway, recent studies indicate a
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growing role for Ptch1 in regulating
apoptosis. The original role for SHH
and Ptch1 in regulating cell survival
came from work in the developing
neuroepithelium, where SHH acts as a
neuronal survival factor (Thibert et al.,
2003). This study demonstrated that
Ptch1 induces apoptosis independent
of Smo and Gli activity by acting as a
dependence receptor, binding caspases,
and inducing apoptosis.
Work from the Balmain lab illumi-
nates a similar role for the multifunc-
tional protein in skin cancer. Previously,
Wakabayashi et al. (2007), in an elegant
forward genetic screen for modifiers of
SCC, found that a single-amino-acid
variant of Ptch1 (T1267N) confers
increased susceptibility to Ras-induced
tumor formation in the FVB/N strain of
mice. Overexpression of the Ptch1FVB
allele driven by the keratin 14 promoter
(K14Ptch1FVB) was sufficient to drive
Ras-induced formation of SCCs in
C57BL/6 mice. In this issue, Kang et al.
(2013) show that forced overexpression
of K14Ptch1FVB results in developmental
malformations consistent with dimini-
shed SHH signaling. Mice displayed
shorter body lengths, lower body
weights, ocular defects, and oligodactyly
with fewer digits with higher K14Ptch1FVB
expression. Although low K14Ptch1FVB
expression did not show pronounced
developmental defects, these mice were
more stable, and they were used to
expand upon the previously reported
Ras-induced SCC formation. To deter-
mine the contribution of K14Ptch1FVB in
adult onset SCC, Ras was mutated by
chemical means (7,12-dimethylbenz[a]
anthracene followed by 12-O-
tetradecanoylphorbol-13-acetate (TPA))
in the skin of adult mice, and tumor for-
mation was measured. This system typi-
cally induces somatic mutation in H-Ras
at codon 61 (CAA to CTA) at high
frequency, causing constitutive activa-
tion and SCC formation similar to that
which is observed in human skin tumors
(Balmain et al., 1984). The authors found
that chemically induced SCC development
increased and tumor latency decreased
in K14Ptch1FVB mice compared with
wild-type mice, despite no significant
change in SHH target gene expression.
They concluded that the K14Ptch1FVB
allele contributes to Ras-induced skin
tumor development in adult mice.
Kang et al. (2013) begin to shed light
on how Ptch1FVB promotes SCC
formation through regulation of Ras-
induced apoptosis (Figure 1). Ptch1FVB
expression suppresses HRAS-induced
apoptosis and Tid1, a tumor suppressor
involved in apoptosis, differentially
binds Ptch1FVB weaker than Ptch1B6
(Wakabayashi et al., 2007). The
authors confirm the strong Tid1–
Ptch1B6 and weak Tid1–Ptch1FVB bind-
ing, and they show that binding
between Tid1–Ptch1B6 decreases after
TPA treatment to levels seen between
Tid1–Ptch1FVB. However, how Ras
influences the Tid1–Ptch1 interaction
needs to be explored further, as expres-
sion of V12HRAS partially inhibits Tid1–
Ptch1B6 and partially promotes Tid1–
Ptch1FVB binding. The authors suggest
that stimulation of mitogen-activated
protein (MAP) kinase signaling from
TPA treatment may also influence
Tid1–Ptch1 binding, as Ptch1 can acti-
vate extracellular signal–regulated
kinase (ERK) independently of Smo
(Chang et al., 2010). In light of the
observation that TPA promotes P-ERK
in the presence of Ptch1B6, but inhibits
P-ERK when Ptch1FVB is expressed,
additional work is needed to determine
whether Ptch1 influences MAP kinase
signaling directly.
Ptch1 lies at a nexus between BCC and
SCC formation
Identification of the Ptch1FVB allele sug-
gests that Ptch1 can have roles in both
BCC and SCC development, inhibiting
BCCs and promoting SCCs. Interestingly,
both tumors appear to share a common
cell of origin, with the interfollicular
epidermis, hair follicle bulge, and hair
germ giving rise to both tumors, depend-
ing on the genetic environment (Epstein,
2011; Lapouge et al., 2011; White et al.,
2011). In mice, p53 loss instigates tumor
growth along with activating signals from
either RAS or SHH. Toggling expression
of RAS or SHH through Ptch1FVB, where
more Ptch1 leads to inhibition of SHH
signaling and promotion of Ras signaling,
provides an interesting and simple way
in which tumor lineages can use the
multiple functions of a single protein to
generate distinct outcomes. Although the
current study focuses on murine skin
cancer, alterations in the Ptch1 locus in
human SCCs appear frequently but are of
unknown significance. Ptch1 function
in preventing apoptosis may be
generalizable to other SHH-dependent
and well as SHH-independent cancers.
Clinical Implications
 Ptch1FVB is a multifunctional protein that regulates hedgehog signaling
and the Ras pathway.
 Ptch1 alleles can promote murine SCC development at the same time that
they inhibit BCC growth.
SCC formation
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Figure 1. Diagram of Patched1 (Ptch1)-dependent squamous cell carcinoma (SCC) tumor formation.
(a) High levels of active RAS and inhibition of Tid1 by Ptch1FVB results in SCC tumor formation but not
maintenance. (b) SCC tumor formation is suppressed in the Ptch1B6 background, where Ptch1B6 is
unable to inhibit Tid1 and results in an increase in Ras-induced apoptosis. Smo, smoothened.
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Additional studies of the enigmatic Ptch1
protein are likely to unveil novel and
illuminating cancer mechanisms.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Atwood SX, Chang ALS, Oro AE (2012) Hedgehog
pathway inhibition and the race against tumor
evolution. J Cell Biol 199:193–7
Balmain A, Ramsden M, Bowden GT et al. (1984)
Activation of the mouse cellular Harvey-ras
gene in chemically induced benign skin
papillomas. Nature 307:658–60
Carpenter D, Stone DM, Brush J et al. (1998)
Characterization of two patched receptors
for the vertebrate hedgehog protein family.
Proc Natl Acad Sci USA 95:13630–4
Chang H, Li Q, Moraes RC et al. (2010) Activation
of Erk by sonic hedgehog independent of
canonical hedgehog signalling. Int J Biochem
Cell Biol 42:1462–71
Epstein EH (2011) Mommy - where do tumors
come from? J Clin Invest 121:1681–3
Hahn H, Wicking C, Zaphiropoulous PG et al.
(1996) Mutations of the human homolog of
Drosophila patched in the nevoid basal cell
carcinoma syndrome. Cell 85:841–51
Hui C-C, Angers S (2011) Gli proteins in develop-
ment and disease. Annu Rev Cell Dev Biol
27:513–37
Ingham PW, Nystedt S, Nakano Y et al. (2000)
Patched represses the Hedgehog signalling
pathway by promoting modification of the
smoothened protein. Curr Biol 10:1315–8
Ingham PW, Nakano Y, Seger C (2011) Mechanisms
and functions of Hedgehog signalling across
the metazoa. Nat Rev Genet 12:393–406
Kang HC, Wakabayashi Y, Jen K-Y et al. (2013)
Ptch1 overexpression drives skin carcinogen-
esis and developmental defects in K14PtchFVB
mice. J Invest Dermatol 133:1311–20
Lapouge G, Youssef KK, Vokaer B et al.Identifying
the cellular origin of squamous skin tumors
(2011) Proc Natl Acad Sci 108:7431–6
Murone M, Rosenthal A, de Sauvage FJ (1999) Sonic
hedgehog signaling by the patched-smooth-
ened receptor complex. Curr Biol 9:76–84
Rohatgi R, Milenkovic L, Scott MP (2007) Patched1
regulates hedgehog signaling at the primary
cilium. Science 317:372–6
Taipale J, Cooper MK, Maiti T et al. (2002) Patched
acts catalytically to suppress the activity of
smoothened. Nature 418:892–7
Thibert C, Teillet MA, Lapointe F et al. (2003)
Inhibition of neuroepithelial patched-induced
apoptosis by sonic hedgehog. Science
301:843–6
Wakabayashi Y, Mao J-H, Brown K et al. (2007)
Promotion of Hras-induced squamous carci-
nomas by a polymorphic variant of the
Patched gene in FVB mice. Nature 445:761–5
White AC, Tran K, Khuu J et al. (2011) Defining the
origins of Ras/p53-mediated squamous cell
carcinoma. Pro Natl Acad Sci 108:7425–30
Applications of Nanoparticles for
Treating Cutaneous Infection
Astrid M. Westendorf1
Today, nanotechnology is finding applications in medicine. The unique physical
and chemical properties of nanoparticles can overcome barriers and allow them
to gain access to biological systems. Because of the increasing prevalence
of microbial resistance to conventional therapies, the development of novel
antimicrobials is imperative. Creating nanotechnology-based drug delivery sys-
tems with antibacterial and immunomodulatory activities may lead to novel
treatments for cutaneous pathogens.
Journal of Investigative Dermatology (2013) 133, 1133–1135. doi:10.1038/jid.2012.412
Nanotechnology is the design and con-
trol of matter that ranges in size
from B1 to 100 nm. The application of
nanotechnology to medicine, known as
nanomedicine, involves the use of pre-
cisely engineered materials in this
size range to develop novel therapeutic
and diagnostic modalities. The unique
physical and chemical properties of
nanoparticles, in particular their small
size and their high surface-to-volume
ratio, can overcome barriers and
allow them to gain access to biological
molecules and systems. These properties
can be used to overcome some of the
limitations of conventional thera-
peutic and diagnostic agents. Therefore,
nanoparticles can be engineered to
serve as vehicles that carry various
therapeutic agents and may be useful
in medical applications, including
targeted drug delivery, vaccine deli-
very, antimicrobials, and immunomodu-
lation (Prow et al., 2011; DeLouise,
2012).
Antimicrobial nanoparticles
Several studies have shown that nano-
particles are advantageous in several
dermatological applications (Papakostas
et al., 2011; DeLouise, 2012). One
important application with respect
to the increasing frequency of micro-
biological resistance to conventional
therapies is the nanotechnology-
based drug delivery with antimicrobial
agents.
Acne is a chronic inflammatory dis-
ease of the pilosebaceous unit. It results
from an androgen-induced increase in
the production of sebum, alterations in
keratinization, inflammation, and bac-
terial colonization of hair follicles on the
face, neck, chest, and back by Propio-
nibacterium acnes. The Gram-positive
bacterium P. acnes is a ubiquitous
member of the skin microbiota and is
found in sebaceous follicles located on
the face and back of most humans.
P. acnes is generally regarded as a com-
mensal of the skin, but certain properties
suggest that it has a pathogenic role in
acne vulgaris. Treatment of acne with
antimicrobial agents has been found to
be associated with the development of
resistance to these agents by P. acnes,
leading to treatment failure. Because
acne often requires long-term treatment
with antibiotics, there are concerns
that the development of resistance
by P. acnes may be associated with
the development of resistance by other
organisms, such as Staphylococcus
aureus and S. pneumoniae. Judicious
use of antibiotics is important, espe-
cially for a common condition such as
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